Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cocrystal Pharma ( (COCP) ) has issued an update.
Cocrystal Pharma announced that its President and co-CEO, Dr. Sam Lee, presented the company’s CDI-988 product candidate at the 9th International Calicivirus Conference in Banff, Alberta, from September 7–11, 2025. CDI-988, the first oral antiviral in development for norovirus infection, has shown promising results in Phase 1 studies, demonstrating a favorable safety profile and broad-spectrum antiviral activity. The FDA has cleared the company to proceed with a Phase 1b human challenge study, marking significant progress in the clinical development of CDI-988, which could impact the treatment and prevention of norovirus infections globally.
The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis. The company utilizes unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
Average Trading Volume: 76,681
Technical Sentiment Signal: Sell
Current Market Cap: $14.77M
For an in-depth examination of COCP stock, go to TipRanks’ Overview page.